Liquid Biopsy Market in United States 2022

March 2022 | 13 pages | ID: L433C4AC7BA4EN
StrategyHelix Inc

Abstracts

A liquid biopsy is a simple and non-invasive alternative to surgical biopsies which enables doctors to discover a range of information about a tumour through a simple blood sample. Traces of the cancer’s DNA in the blood can give clues about which treatments are most likely to work for that patient. According to StrategyHelix, the liquid biopsy market in United States is expected to increase by US$ 3,801 million during 2022-2028, expanding at a CAGR of 11.7% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for liquid biopsy. The United States liquid biopsy market is segmented on the basis of product, therapy, application, and technology. Based on product, the liquid biopsy market in United States is categorized into kits and reagents, instruments, tests/services. On the basis of therapy, the liquid biopsy market in United States has been segmented into noninvasive prenatal testing (NIPT), oncology, others. By application, the liquid biopsy market in United States has been segmented into therapy guidance, diagnosis/screening, treatment monitoring. Based upon technology, the liquid biopsy market in United States is categorized into NGS, PCR, others.

The United States liquid biopsy market is highly competitive. The liquid biopsy market is dominated by key players, which are Exact Sciences Corp., F. Hoffmann-La Roche AG, Guardant Health Inc., Illumina Inc., Invitae Corp., Laboratory Corporation of America Holdings (Labcorp), Natera Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Sysmex Inostics Inc.

Report Scope
Product: kits and reagents, instruments, tests/services
Therapy: noninvasive prenatal testing (NIPT), oncology, others
Application: therapy guidance, diagnosis/screening, treatment monitoring
Technology: NGS, PCR, others
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders
Get a comprehensive picture of the United States liquid biopsy market
Identify regional strategies and strategic priorities on the basis of local data
Pinpoint growth sectors and trends for investment

Contents

PART 1. INTRODUCTION

Scope of the study
Study period
Geographical scope
Research methodology

PART 2. LIQUID BIOPSY MARKET OVERVIEW

PART 3. MARKET BREAKDOWN BY PRODUCT

Kits and reagents
Instruments
Tests/services

PART 4. MARKET BREAKDOWN BY THERAPY

Noninvasive prenatal testing (NIPT)
Oncology
Others

PART 5. MARKET BREAKDOWN BY APPLICATION

Therapy guidance
Diagnosis/screening
Treatment monitoring

PART 6. MARKET BREAKDOWN BY TECHNOLOGY

NGS
PCR
Others

PART 7. KEY COMPANIES

Exact Sciences Corp.
F. Hoffmann-La Roche AG
Guardant Health, Inc.
Illumina, Inc.
Invitae Corp.
Laboratory Corporation of America Holdings (Labcorp)
Natera, Inc.
QIAGEN N.V.
Quest Diagnostics Incorporated
Sysmex Inostics Inc.
About StrategyHelix
Disclaimer